Stock comparison
IDEXX Laboratories
Innoviva
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
INVA
Innoviva
Market cap
$1.66B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | INVA | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 51C | IDXX |
| Benjamin Graham | 80A | 50C | IDXX |
| Philip Fisher | 75B | 44D | IDXX |
| Peter Lynch | 71B | 16F | IDXX |
| Joel Greenblatt | 83C | 32F | IDXX |
| Charlie Munger | 87A | 47D | IDXX |
| Terry Smith | 84A | 46D | IDXX |
Side-by-side metrics
| Metric | IDXX | INVA |
|---|---|---|
| Market cap | $44.12B | $1.66B |
| P/E (TTM) | 39.0x | 3.3x |
| EV/EBIT | 31.6x | 8.6x |
| ROIC (TTM) | 40.66% | 2.93% |
| Gross margin | 62.05% | 76.2% |
| Net margin | 24.63% | 118.91% |
| Revenue CAGR 5y | 7.56% | 2.06% |
| EPS CAGR 5y | 10.79% | 5.54% |
| Debt / Equity | 0.7x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $1.66B+96%
- ROIC (TTM)40.66%vs 2.93%+93%
- Revenue CAGR 5y7.56%vs 2.06%+73%
- EPS CAGR 5y10.79%vs 5.54%+49%
INVA leads on
- P/E (TTM)3.3xvs 39.0x+91%
- Net margin118.91%vs 24.63%+79%
- EV/EBIT8.6xvs 31.6x+73%
- Debt / Equity0.2xvs 0.7x+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.